Skip to content
🌐 Global🇮🇳 India📍 Asia-Pacific📍 Bihar📍 Delhi-NCR📍 East India📍 Europe📍 Gujarat📍 Karnataka📍 Kerala📍 Madhya Pradesh📍 Maharashtra📍 Middle East📍 North India📍 Northeast India📍 Punjab📍 Rajasthan📍 South India📍 Tamil Nadu📍 Telangana📍 United Kingdom📍 United States📍 Uttar Pradesh📍 West Bengal📍 West India
LIVE
New EU industry rules would damage UK, warns Burnham◆US Gasoline, Distillate Inventories Continue to Fall as Crude Stocks Hold◆What is your dog really saying? AI is helping researchers decode animal communication◆Short 'logic check' warnings may improve how people assess climate arguments◆Global Energy Demand Set to Jump 60% by 2060 as Developing Nations Power Up◆Plot targeting Manchester's Jewish community disrupted, say police◆Why Apple could soon join Nvidia in the exclusive $5 trillion club◆Two Ole Miss students found dead in separate incidents, with kratom found at both scenes - New York Post◆New EU industry rules would damage UK, warns Burnham◆US Gasoline, Distillate Inventories Continue to Fall as Crude Stocks Hold◆What is your dog really saying? AI is helping researchers decode animal communication◆Short 'logic check' warnings may improve how people assess climate arguments◆Global Energy Demand Set to Jump 60% by 2060 as Developing Nations Power Up◆Plot targeting Manchester's Jewish community disrupted, say police◆Why Apple could soon join Nvidia in the exclusive $5 trillion club◆Two Ole Miss students found dead in separate incidents, with kratom found at both scenes - New York Post◆
Home / Global Markets
Global Markets

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock soared.

MarketWatchSeptember 22, 20261 min read
Share this story
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock soared.

marketsworld
📡 Verified Wire Agency Verified Resource & Provenance
Original Resource
MarketWatch
Read Wire Dispatch → Share on 𝕏
✉
The Next Brief
Get the day's most important stories in one email
AI-curated morning digest. No noise. Unsubscribe anytime.

Comments 0

Advertisement

Related stories

Global Markets
Why Apple could soon join Nvidia in the exclusive $5 trillion club
MarketWatch · September 22, 2026
Global Markets
Want to retire with more money? Leave the U.S. early in your career — and then come back.
MarketWatch · September 22, 2026
Global Markets
Want to bet on risky, high-beta stocks? Why you should wait for this week in October.
MarketWatch · September 22, 2026
Global Markets
Nearly half of adults under 30 live with their parents. The financial fallout could last for decades.
MarketWatch · September 22, 2026

Most read

  1. 1Karnataka launches action plan to cut salt intake by 30% by 2030Top Stories
  2. 2Orbital Light Sails Demonstrate Momentum Capture from Photons in Low Earth OrbitScience
  3. 3The Speed Advantage of Modern Power InfrastructureEnvironment
  4. 4New EU industry rules would damage UK, warns BurnhamBusiness
  5. 5US Gasoline, Distillate Inventories Continue to Fall as Crude Stocks HoldFinance